Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: Major thromboembolic and hemorrhagic complications

Canadian Journal of Surgery

Volumn 42, Issue 1, 1999, Pages 27-36

  Jamieson, W R Eric ^a   Miyagishima, Robert T ^a   Grunkemeier, Gary L ^a   Germann, Eva ^a   Henderson, Charmaine ^a   Lichtenstein, Samuel V ^a   Ling, Hilton ^a   Munro, A Ian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ANTICOAGULATION; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; ARTICLE; DEVICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; EQUIPMENT FAILURE ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; REOPERATION; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 0032970744     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical prostheses. J Heart Valve Dis 1993;2(3):291-301.
2. Khan S, Chaux A, Matloff J, Blanche C, DeRobertis M, Kass R, et al. The St. Jude Medical valve. Experience with 1000 cases. J Thorac Cardiovasc Surg 1994;108(6):1010-20.
3. Kratz JM, Crawford FA Jr, Sade RM, Crumbley AJ, Stroud MR. St. Jude prosthesis for aortic and mitral valve replacement: a ten-year experience. Ann Thorac Surg 1993;56(3):462-8.
4. Baudet EM, Puel V, McBride JT, Grimaud JP, Roques F, Clerc F, et al. Long-term results of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1995;109 (5):858-70.
5. Ibrahim M, O'Kane H, Cleland J, Gladstone D, Sarsam M, Patterson C. The St. Jude Medical prosthesis. A thirteen-year experience. J Thorac Cardiovasc Surg 1994;108(2):221-30.
6. Aoyagi S, Oryoji A, Nishi Y, Tanaka K, Kosuga K, Oishi K. Long-term results of valve replacement with the St. Jude Medical valve. J Thorac Cardiovasc Surg 1994;108(6):1021-9.
7. Fernandez J, Laub GW, Adkins MS, Anderson WA, Chen C, Bailey BM, et al. Early and late-phase events after valve replacement with the St. Jude Medical prosthesis in 1200 patients. J Thorac Cardiovasc Surg 1994;107 (2):394-407.
8. Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994;107(4):1136-45.
9. Nakano K, Koyanagi H, Hashimoto A, Kitamura M, Endo M, Nagashima M, et al. Twelve years' experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg 1994;57(3):697-703.
10. Smith JA, Westlake GW, Mullerworth MH, Skillington PD, Tatoulis J. Excellent long-term results of cardiac valve replacement with the St. Jude Medical valve prosthesis. Circulation 1993;88 (5 Pt 2):II49-54.
11. Aagaard J, Hansen CN, Tingleff J, Rygg I. Seven-and-a-half years clinical experience with the CarboMedics prosthetic heart valve. J Heart Valve Dis 1995;4(6):628-33.
12. Copeland JG 3d. An international experience with the CarboMedics prosthetic heart valve. J Heart Valve Dis 1995;4(1):56-62.
13. Copeland JG 3d, Sethi GK for the CarboMedics prosthetic heart valve. Four-year experience with the CarboMedics valve: the North American experience. Ann Thorac Surg 1994;58(3):630-8.
14. de Luca L, Vitale N, Giannolo B, Cafarella G, Piazza L, Cotrufo M. Midterm follow-up after heart valve replacement with CarboMedics bileaflet prostheses. J Thorac Cardiovasc Surg 1993;106(6):1158-65.
15. Fiane AE, Saatvedt K, Svennevig JL, Geiran O, Nordstrand K, Frfysaker T. The CarboMedics valve: midterm follow-up with analysis of risk factors. Ann Thorac Surg 1995;60(4):1053-8.
16. Jamieson WRE, Munro AI, Miyagishima RT, Allen P, Burr LH, Tyers GF. Carpentier-Edwards standard porcine bioprosthesis: clinical performance to seventeen years. Ann Thorac Surg 1995;60(4):999-1007.
17. Jamieson WRE, Rosado LJ, Munro AI, Gerein AN, Burr LH, Miyagashima RT, et al: Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups. Ann Thorac Surg 1988;46(2):155-62.
18. Jamieson WRE, Tyers GF, Janusz MT, Miyagishima RT, Munro AI, Ling H, et al: Age as a determinant for selection of porcine bioprostheses for cardiac valve replacement: experience with Carpentier-Edwards standard bioprosthesis. Can J Cardiol 1991;7(4):181-8.
19. Burr LH, Jamieson WRE, Munro AI, Miyagishima RT, Germann E. Porcine bioprostheses in the elderly: clinical performance by age groups and valve positions. Ann Thorac Surg 1995;60(2 Suppl):S264-9.
20. Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1996;62 (3):932-5.
21. Bodnar E, Butchart EG, Bamford J, Bessekar AM, Grunkemeier GL, Frater RW. Proposal for reporting thrombosis, embolism and bleeding after heart valve replacement. J Heart Valve Dis 1994;3(2):120-3.
22. O'Brien MF, Stafford EG, Gardner MA, Pohlner PG, Tesar PJ, Cochrane AD, et al. Allograft aortic valve replacement: long-term follow-up. Ann Thorac Surg 1995;60(2 Suppl):S65-70.
23. Pelletier LC, Carrier M, Leclerc Y, Dyrda I, Gosselin G. Influence of age on late results of valve replacement with porcine bioprostheses. J Cardiovasc Surg (Torino) 1992;33(5):526-33.
24. Pelletier LC, Carrier M, Leclerc Y, Dyrda I. The Carpentier-Edwards pericardial bioprosthesis: clinical experience with 600 patients. Ann Thorac Surg 1995;60(2 Suppl):S297-302.
25. Pupello DF, Bessone LN, Hiro SP, Lopez-Cuenca E, Glatterer MS Jr, Angell WW, et al. Bioprosthetic valve longevity in the elderly: an 18-year longitudinal study. Ann Thorac Surg 1995:60(2Suppl):S270-5.
26. Elkins RC, Knott-Craig CJ, Ward KE, McCue C, Lane MM. Pulmonary autograft in children: realized growth potential. Ann Thorac Surg 1994;57(6): 1387-94.
27. David TE, Bos J, Rakowski H. Aortic valve replacement with the Toronto SPV bioprosthesis. J Heart Valve Dis 1992;1(2):244-8.
28. Jin XY, Gibson DG, Yacoub MH, Pepper JR. Perioperative assessment of aortic homograft, Toronto stentless valve, and stented valve in the aortic position. Ann Thorac Surg 1995;60(2 Suppl):S395-401.
29. Sintek CF, Fletcher AD, Khonsari S. Stentless porcine aortic root: Valve of choice for the elderly patient with small aortic root? J Thorac Cardiovasc Surg 1995;109(5):871-6.
30. Wong K, Shad S, Waterworth PD, Khaghani A, Pepper JR, Yacoub MH. Early experience with the Toronto stentless porcine valve. Ann Thorac Surg 1995;60(2 Suppl):S402-5.
31. Sim EK, Orszulak TA, Schaff HV, Shub C. Influence of prosthesis size on change in left ventricular mass following aortic valve replacement. Eur J Cardiothorac Surg 1994;8(6):293-7.
32. Gohlke-Bärwolf C, Acar J, Burckhardt D, Oakley C, Butchart E, Krayenbuhl P et al, Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Dis 1993;2 (4):398-410.
33. Butchart EG. Prosthesis-specific and patient-specific anticoagulation. In: Butchart EG, Bodnar E, editors. Current issues in heart valve disease, thrombosis, embolism and bleeding. London (UK): ICR Publishers; 1992. p. 293.
34. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 1991;84(5 Suppl):III61-9.
35. Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69(4):316-20.
36. Horstkotte D, Bergemann R, Althaus U, Babin-Ebell J, Chares M, Dahm M, et al. German experience with low intensity anticoagulation (GELIA): protocol of a multi-center randomized, prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993; 2(4):411-9.
37. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108(Suppl 4): 371S-379S.
38. White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Letgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med 1989;111(9):730-7.
39. Hirsh J, Deykin D, Poller L. Therapeutic range for oral anticoagulation therapy. Chest 1986;89(2 Suppl):11S-15S.
40. Skudicky D, Essop MR, Wisenbaugh T, Skoularigis J, Essop AR, Dullabh A, et al. Frequency of prosthetic valve-related complications with very low level warfarin anticoagulation combined with dipyridamole after valve replacement using St. Jude Medical prostheses. Am J Cardiol 1994;74(11):1137-41.
41. Altman R, Rouvier J, Gurfinkel E, D'Ortencio O, Manazanel R, de La Fuente L, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101(3): 427-31.
42. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl JMed 1990;322 (7):428-32.
43. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation 1994;89(3):1469-80.
44. Butchart EG, Lewis PA, Grunkemeier GL, Kulatilake N, Breckenridge IM. Low risk of thrombosis and serious emboli events despite low-intensity anticoagulation. Experience with 1,004 Medtronic Hall valves. Circulation 1988;78(3 Pt 2):I66-77.
45. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329(8):524-9.
46. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51(9):1537-41.
47. Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetyl-salicylic acid: a controlled clinical study in patients with aortic ball devices. Am Heart J 1977;94(1):101-11.